Cargando…

Evidence for Cardiorenal Protection with SGLT-2 Inhibitors and GLP-1 Receptor Agonists in Patients with Diabetic Kidney Disease

For almost two decades, the management of patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) was based on the optimal glycemic and blood pressure control as well as on the adequate blockade of the renin-angiotensin-system. Over the past few years, sodium-glucose co-transp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Georgianos, Panagiotis I., Vaios, Vasilios, Roumeliotis, Stefanos, Leivaditis, Konstantinos, Eleftheriadis, Theodoros, Liakopoulos, Vassilios
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8874759/ https://www.ncbi.nlm.nih.gov/pubmed/35207711 http://dx.doi.org/10.3390/jpm12020223

Ejemplares similares

Therapeutic Advances in Diabetic Kidney Disease
por: Georgianos, Panagiotis I., et al.
Publicado: (2023)

Expression of Circulating MicroRNAs Linked to Bone Metabolism in Chronic Kidney Disease-Mineral and Bone Disorder
por: Yavropoulou, Maria P., et al.
Publicado: (2020)

APD or CAPD: one glove does not fit all
por: Roumeliotis, Athanasios, et al.
Publicado: (2020)

Oxidized LDL Modifies the Association between Proteinuria and Deterioration of Kidney Function in Proteinuric Diabetic Kidney Disease
por: Roumeliotis, Stefanos, et al.
Publicado: (2021)

10-year-long survival in a PD patient with severe calcifying encapsulating peritoneal sclerosis treated with tamoxifen: a case-report
por: Liakopoulos, Vassilios, et al.
Publicado: (2020)

Hypertension in Dialysis Patients: Diagnostic Approaches and Evaluation of Epidemiology
por: Georgianos, Panagiotis I., et al.
Publicado: (2022)

Dietary Antioxidant Supplements and Uric Acid in Chronic Kidney Disease: A Review
por: Roumeliotis, Stefanos, et al.
Publicado: (2019)

Oxidative Stress and the Kidney in the Space Environment
por: Pavlakou, Paraskevi, et al.
Publicado: (2018)

The Association of dp-ucMGP with Cardiovascular Morbidity and Decreased Renal Function in Diabetic Chronic Kidney Disease
por: Roumeliotis, Stefanos, et al.
Publicado: (2020)

Should We Use Dialyzable β-Blockers in Hemodialysis?
por: Georgianos, Panagiotis I., et al.
Publicado: (2022)

Making a case for the combined use of SGLT2 inhibitors and GLP1 receptor agonists for cardiorenal protection
por: Sridhar, Vikas S., et al.
Publicado: (2020)

Red Blood Cell Distribution Width Is Associated with Deterioration of Renal Function and Cardiovascular Morbidity and Mortality in Patients with Diabetic Kidney Disease
por: Roumeliotis, Stefanos, et al.
Publicado: (2020)

Oxidized LDL Is Associated with eGFR Decline in Proteinuric Diabetic Kidney Disease: A Cohort Study
por: Roumeliotis, Stefanos, et al.
Publicado: (2021)

Vascular Calcification in Chronic Kidney Disease: The Role of Vitamin K- Dependent Matrix Gla Protein
por: Roumeliotis, Stefanos, et al.
Publicado: (2020)

Vitamin K Supplementation for Prevention of Vascular Calcification in Chronic Kidney Disease Patients: Are We There Yet?
por: Roumeliotis, Stefanos, et al.
Publicado: (2022)

The Relation of Clinic and Ambulatory BP with the Risk of Cardiovascular Events and All-Cause Mortality among Patients on Peritoneal Dialysis
por: Georgianos, Panagiotis I., et al.
Publicado: (2021)

N-Acetylcysteine: more than preventing contrast-induced nephropathy in uremic patients—focus on the antioxidant and anti-inflammatory properties
por: Cepaityte, Dainora, et al.
Publicado: (2023)

Feeding during Dialysis Increases Intradialytic Blood Pressure Variability and Reduces Dialysis Adequacy
por: Fotiadou, Elena, et al.
Publicado: (2022)

VItamin K In PEritonial DIAlysis (VIKIPEDIA): Rationale and study protocol for a randomized controlled trial
por: Roumeliotis, Stefanos, et al.
Publicado: (2022)

Association of the Inactive Circulating Matrix Gla Protein with Vitamin K Intake, Calcification, Mortality, and Cardiovascular Disease: A Review
por: Roumeliotis, Stefanos, et al.
Publicado: (2019)

Combination Treatment of SGLT2 Inhibitors and GLP-1 Receptor Agonists: Symbiotic Effects on Metabolism and Cardiorenal Risk
por: Goncalves, Edison, et al.
Publicado: (2018)

Antioxidant Supplementation in Renal Replacement Therapy Patients: Is There Evidence?
por: Liakopoulos, Vassilios, et al.
Publicado: (2019)

Unfavorable Effects of Peritoneal Dialysis Solutions on the Peritoneal Membrane: The Role of Oxidative Stress
por: Roumeliotis, Stefanos, et al.
Publicado: (2020)

Oxidative Stress in Patients Undergoing Peritoneal Dialysis: A Current Review of the Literature
por: Liakopoulos, Vassilios, et al.
Publicado: (2017)

Icodextrin-associated generalized exfoliative skin rash in a CAPD patient: a case-report
por: Liakopoulos, Vassilios, et al.
Publicado: (2018)

Association between Biomarkers of Oxidative Stress and Inflammation with Cardiac Necrosis and Heart Failure in Non-ST Segment Elevation Myocardial Infarction Patients and Various Degrees of Kidney Function
por: Roumeliotis, Stefanos, et al.
Publicado: (2021)

Oxidative Stress Genes in Diabetes Mellitus Type 2: Association with Diabetic Kidney Disease
por: Roumeliotis, Athanasios, et al.
Publicado: (2021)

Molecular Mechanisms of SGLT2 Inhibitor on Cardiorenal Protection
por: Hou, Yi-Chou, et al.
Publicado: (2020)

An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors
por: Salvatore, Teresa, et al.
Publicado: (2022)

Animal models in peritoneal dialysis
por: Nikitidou, Olga, et al.
Publicado: (2015)

The effect of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors on cardiorenal outcomes: a network meta-analysis of 23 CVOTs
por: Giugliano, Dario, et al.
Publicado: (2022)

SGLT2 Inhibitors vs. GLP-1 Agonists to Treat the Heart, the Kidneys and the Brain
por: Rolek, Bartosz, et al.
Publicado: (2023)

Cardiorenal and other diabetes related outcomes with SGLT-2 inhibitors compared to GLP-1 receptor agonists in type 2 diabetes: nationwide observational study
por: Lugner, Moa, et al.
Publicado: (2021)

Redox Systems Biology in Chronic Kidney Disease
por: Roumeliotis, Stefanos, et al.
Publicado: (2023)

COVID-19 and the kidney: time to take a closer look
por: Liakopoulos, Vassilios, et al.
Publicado: (2021)

Cardiorenal protection of SGLT2 inhibitors—Perspectives from metabolic reprogramming
por: Gao, Yue-Ming, et al.
Publicado: (2022)

Decreasing High Failure Rate of Vaccinations in Patients With Chronic Kidney Disease; not Just a Matter of Quantity
por: Eleftheriadis, Theodoros, et al.
Publicado: (2012)

SGLT2 Inhibitor–Induced Sympathoinhibition: A Novel Mechanism for Cardiorenal Protection
por: Herat, Lakshini Y., et al.
Publicado: (2020)

The expanding role of SGLT2 inhibitors beyond glucose-lowering to cardiorenal protection
por: Brown, Emily, et al.
Publicado: (2021)

Oxidative Stress in the Pathogenesis and Evolution of Chronic Kidney Disease: Untangling Ariadne’s Thread
por: Duni, Anila, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_acon8ri2gdo47ojstvu045o0vr